Article Type
Article
Abstract
Acute myeloid leukemia (AML) is a malignancy of proliferative, clonal, abnormally, or poorly differentiated cells of the hematopoietic system, characterized by clonal evolution and genetic heterogeneity. Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation. FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML. In this systematic review and meta-analysis, we present a detailed review of current clinical evidence of FLT3 inhibitors and their use in AML, and discrepancies association between FLT3 inhibitors use and prognosis of acute myeloid leukemia and maintenance setting.
Keywords
FLT3 inhibitors, Acute myeloid leukemia, Systematic review, FMS-like tyrosine kinase 3
Recommended Citation
Yousif, Nasser Ghaly
(2025)
"Discrepancies association between FLT3 inhibitors use and prognosis of acute myeloid leukemia: systematic review and meta-analysis,"
Muthanna Medical Journal: Vol. 9:
Iss.
2, Article 7.
Available at:
https://muthmj.researchcommons.org/journal/vol9/iss2/7
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.